export const therapeuticProcedures = {
  id: 'therapeutic-procedures',
  title: 'Therapeutic Procedures',
  subsections: {
    icdImplantationIndications: {
      title: 'ICD Implantation Indications',
      subsections: {
        generalPrinciples: {
          title: 'General Principles',
          evidenceLevels: ['B', 'C', 'D'],
          content: '**Evidence Level B**: As per ACC/AHA/AMSSM/…/SCMR 2024 guidelines: Apply individual clinical judgment when assessing the prognostic strength of conventional risk markers within the clinical profile of the individual patient, and a thorough and balanced discussion of the evidence, benefits, and estimated risks to engage the fully informed patient\'s active participation in decision-making of placing an ICD.\n\n**Evidence Level C**: \n- Consider obtaining echocardiography-derived LA diameter and maximal LVOT gradient in patients aged ≥ 16 years with HCM to aid in calculating an estimated 5-year sudden death risk to be used in shared decision-making for ICD implantation.\n- Consider discussing the estimated 5-year sudden death risk and mortality rates during the shared decision-making process for ICD implantation in patients with HCM with ≥ 1 major SCD risk factors.\n- Consider offering ICD implantation in adult patients with HCM with ≥ 1 major risk factors for SCD, including: sudden death judged definitively or likely attributable to HCM in ≥ 1 first-degree or close relatives aged ≤ 50 years; massive LVH ≥ 30 mm in any LV segment; ≥ 1 recent episodes of syncope suspected by clinical history to be arrhythmic; LV apical aneurysm with transmural scar or late gadolinium enhancement; LV systolic dysfunction (ejection fraction < 50%)\n- Consider performing ICD implantation in patients with HCM and persistent LVEF < 50%.\n- Consider performing ICD implantation in patients with extensive late gadolinium enhancement by contrast-enhanced cardiovascular MRI or nonsustained VT present on ambulatory monitoring in selected adult patients with HCM and without major SCD risk factors after clinical assessment, or if the decision to proceed with ICD implantation remains otherwise uncertain.\n\n**Evidence Level D**: \n- Do not perform ICD implantation in patients with HCM without risk factors.\n- Do not perform ICD implantation in patients with HCM for the sole purpose of participation in competitive sports.\n\n**Evidence Level B**: As per ESC 2023 guidelines: \n- Obtain comprehensive SCD risk stratification in all patients with cardiomyopathy not suffered a previous cardiac arrest/sustained ventricular arrhythmia at initial evaluation and at 1-2 year intervals or whenever a change in clinical status occurs.\n- Use validated SCD algorithms/scores as aids to the shared decision-making when offering ICD implantation, where available, in patients with HCM.\n- Perform ICD implantation in patients with HCM with a history of survived cardiac arrest due to VT or VF or spontaneous sustained ventricular arrhythmia causing syncope or hemodynamic compromise in the absence of reversible causes.\n- Perform ICD implantation only in patients with an expected good quality survival > 1 year.\n- Guide ICD implantation by shared decision-making that is evidence-based, takes into account the patient\'s individual preferences, beliefs, circumstances, and values, and ensures that the patient understands the benefits, harms, and possible consequences of different treatment options.\n\n**Evidence Level C**: \n- Consider obtaining comprehensive SCD risk stratification to evaluate the need for ICD implantation in patients with cardiomyopathy requiring pacemaker implantation.\n- Consider performing ICD implantation in patients with cardiomyopathy presenting with hemodynamically tolerated VT in the absence of reversible causes.\n\n**Evidence Level D**: Do not perform ICD implantation in patients with incessant ventricular arrhythmias until the ventricular arrhythmia is controlled.'
        },
        lowRiskScd: {
          title: '<4% Risk of SCD',
          evidenceLevel: 'C',
          content: '**Evidence Level C**: As per ESC 2023 guidelines: \n- Consider discussing prophylactic ICD implantation in shared decision-making with patients in the low-risk category (< 4% estimated 5-year risk of SCD) in the presence of extensive late gadolinium enhancement (≥ 15%) on cardiac MRI recognizing the lack of robust data on the impact of scar quantification on the personalized risk estimates generated by HCM Risk-SCD or a validated pediatric model (such as HCM Risk-Kids).\n- Consider discussing prophylactic ICD implantation in shared decision-making with patients in the low-risk category (< 4% estimated 5-year risk of SCD) in the presence of LVEF < 50% recognizing the lack of robust data on the impact of systolic dysfunction on the personalized risk estimates generated by HCM Risk-SCD or a validated pediatric model (such as HCM Risk-Kids).\n\n**Evidence Level C**: As per ESC 2022 guidelines, consider performing ICD implantation in ≥ 16 years old patients with HCM with a low (< 4%) estimated 5-year risk of SCD and significant late gadolinium enhancement at cardiac MRI (usually ≥ 15% of LV mass), LVEF < 50%, or LV apical aneurysm.'
        },
        moderateRiskScd: {
          title: '4-6% Risk of SCD',
          evidenceLevel: 'C',
          content: '**Evidence Level C**: As per ESC 2023 guidelines, consider performing ICD implantation in individual patients with an estimated 5-year risk of SCD of between ≥ 4% and < 6%, following detailed clinical assessment taking into account the lifelong risk of complications and the impact of an ICD on lifestyle, socioeconomic status, and psychological health.\n\n**Evidence Level C**: As per ESC 2022 guidelines, consider performing ICD implantation in ≥ 16 years old patients with HCM with an estimated 5-year risk of SCD of ≥ 4 to < 6% and with significant late gadolinium enhancement at cardiac magnetic resonance (usually ≥ 15% of LV mass), LVEF < 50%, abnormal BP response during the exercise test, LV apical aneurysm, or presence of a sarcomeric pathogenic mutation.'
        },
        highRiskScd: {
          title: '≥6% Risk of SCD',
          evidenceLevel: 'C',
          content: '**Evidence Level C**: As per ESC 2023 guidelines, consider performing ICD implantation in patients with an estimated 5-year risk of sudden death of ≥ 6%, following a detailed clinical assessment taking into account the lifelong risk of complications, competing mortality risk from the disease and comorbidities, and the impact of an ICD on lifestyle, socioeconomic status, and psychological health.\n\n**Evidence Level C**: As per ESC 2022 guidelines, consider performing ICD implantation in ≥ 16 years old patients with HCM with an estimated 5-year risk of sudden death of ≥ 6%.'
        },
        postCardiacArrest: {
          title: 'Post Cardiac Arrest',
          evidenceLevel: 'B',
          content: '**Evidence Level B**: As per ACC/AHA/AMSSM/…/SCMR 2024 guidelines, perform ICD implantation in patients with HCM and a previous documented cardiac arrest or sustained VT.\n\n**Evidence Level B**: As per ESC 2023 guidelines, perform ICD implantation in patients with a history of survived cardiac arrest due to VT or VF or spontaneous sustained VT with hemodynamic compromise.\n\n**Evidence Level B**: As per ESC 2022 guidelines: Perform ICD implantation in patients with HCM with hemodynamically not-tolerated VT or VF.\n\n**Evidence Level C**: Consider performing ICD implantation in patients with HCM presenting with hemodynamically tolerated sustained monomorphic VT.\n\n**Evidence Level B**: As per ACC/AHA/HRS 2018 guidelines, perform ICD implantation in patients with HCM survived a sudden cardiac arrest due to VT or VF, or having spontaneous sustained VT causing syncope or hemodynamic compromise, if the expected meaningful survival is > 1 year.'
        },
        pediatricPatients: {
          title: 'Pediatric Patients',
          evidenceLevels: ['B', 'C'],
          content: '**Evidence Level C**: As per ACC/AHA/AMSSM/…/SCMR 2024 guidelines: \n- Consider performing ICD implantation in pediatric patients with HCM having ≥ 1 conventional risk factors, including unexplained syncope, massive LVH, nonsustained VT, or family history of early HCM-related SCD, after considering the relatively high complication rates of long-term ICD implantation in younger patients.\n- Consider taking into account additional factors, such as extensive late gadolinium enhancement on contrast-enhanced cardiac MRI and systolic dysfunction, in risk stratification for ICD shared decision-making in pediatric patients with HCM.\n\n**Evidence Level C**: As per ESC 2022 guidelines, consider performing ICD implantation in < 16 years old pediatric patients with HCM with an estimated 5-year risk of sudden death of ≥ 6% (based on HCM Risk-Kids score).\n\n**Evidence Level B**: As per ESC 2014 guidelines: \n- Perform implantation of an ICD in pediatric patients survived a cardiac arrest or experienced documented sustained VT.\n- Perform implantation of an ICD in pediatric patients with ≥ 2 major pediatric risk factors, after appropriate counseling, and when an assessment of the lifelong risk of complications and the impact of an ICD on lifestyle and psychological health suggests a net benefit from ICD therapy.\n\n**Evidence Level C**: Consider performing implantation of an ICD in pediatric patients with a single major pediatric risk factor, after appropriate counseling, and when an assessment of the lifelong risk of complications and the impact of an ICD on lifestyle and psychological health suggests a net benefit from ICD therapy.'
        },
        technicalConsiderations: {
          title: 'Technical Considerations',
          evidenceLevels: ['A', 'B', 'C'],
          content: '**Evidence Level B**: As per ACC/AHA/AMSSM/…/SCMR 2024 guidelines: \n- Use either a single-chamber transvenous ICD or a subcutaneous ICD in patients with HCM receiving an ICD after a shared decision-making discussion, taking into account patient preferences, age, lifestyle, and potential need for pacing for bradycardia or VT termination.\n- Use single-coil ICD leads in preference to dual-coil leads if defibrillation threshold is deemed adequate in patients with HCM receiving a transvenous ICD.\n- Program antitachycardia pacing to minimize the risk of shocks in patients with HCM and pacing-capable ICD.\n\n**Evidence Level C**: \n- Consider using a dual-chamber ICD in patients with HCM receiving an ICD with a need for atrial or atrioventricular sequential pacing for bradycardia/conduction abnormalities, or as an attempt to relieve symptoms of obstructive HCM (most commonly in patients aged > 65 years).\n- Consider offering CRT to improve symptoms in patients with HCM and LVEF < 50%, having NYHA class II-IV HF despite guideline-directed medical therapy, and LBBB.\n- Consider offering CRT to improve symptoms in selected adult patients with nonobstructive HCM receiving an ICD and having NYHA class II-IV HF, LBBB, and LVEF < 50%.\n- Consider using a dual-chamber ICD in patients with HCM and paroxysmal ATs or AF, if a decision has been made for ICD implantation, while balancing the decision against higher complication rates of dual-chamber devices.\n\n**Evidence Level A**: As per ESC 2023 guidelines: Evaluate patients for eligibility for CRT when an ICD is indicated.\n\n**Evidence Level B**: Counsel patients before ICD implantation on the risk of inappropriate shocks, implant complications, and the social, occupational, and driving implications of the device.\n\n**Evidence Level C**: \n- Consider placing subcutaneous defibrillators as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia, cardiac resynchronization, or anti-tachycardia pacing is not anticipated.\n- Consider using wearable cardioverter-defibrillator in adult patients with a secondary prevention ICD indication temporarily ineligible for ICD implantation.'
        }
      }
    },
    catheterAblation: {
      title: 'Catheter Ablation',
      subsections: {
        ventricularArrhythmia: {
          title: 'Ventricular Arrhythmia',
          evidenceLevel: 'C',
          content: '**Evidence Level C**: As per ACC/AHA/AMSSM/…/SCMR 2024 guidelines, consider performing catheter ablation to reduce arrhythmia burden in patients with HCM and recurrent symptomatic sustained monomorphic VT, or recurrent ICD shocks despite optimal device programming, and if antiarrhythmic drug therapy is either ineffective, not tolerated, or not preferred.\n\n**Evidence Level C**: As per ESC 2022 guidelines, consider performing catheter ablation in selected patients with HCM and recurrent, symptomatic sustained monomorphic VT or ICD shocks for sustained monomorphic VT, if antiarrhythmic drugs are ineffective, contraindicated, or not tolerated.'
        },
        atrialFibrillation: {
          title: 'Atrial Fibrillation',
          evidenceLevels: ['B', 'C'],
          content: '**Evidence Level C**: As per ACC/AHA/AMSSM/…/SCMR 2024 guidelines: \n- Consider performing catheter ablation as part of rhythm control strategy in patients with HCM and symptomatic AF if pharmacological therapy is ineffective, contraindicated, or not the patient\'s preference.\n- Consider performing concomitant surgical AF ablation for rhythm control in patients with HCM and AF requiring surgical myectomy.\n\n**Evidence Level B**: As per ESC 2023 guidelines: \n- Perform catheter ablation for rhythm control after one failed or intolerant class I or III antiarrhythmic drug to improve symptoms of recurrences in patients with paroxysmal or persistent AF and cardiomyopathy.\n- Perform catheter ablation to reverse LV dysfunction in patients with AF when tachycardia-induced component is highly probable, independent of their symptom status.\n\n**Evidence Level C**: \n- Consider ensuring maintenance of sinus rhythm rather than rate control at an early stage in patients with AF without major risk factors for recurrence, regardless of symptoms.\n- Consider performing catheter ablation as first-line rhythm control therapy as an alternative to class I or III antiarrhythmic drugs, considering patient choice, benefit, and risk, to improve symptoms in selected patients with paroxysmal or persistent AF without major risk factors for recurrences.\n- Consider performing catheter ablation to prevent AF recurrences and improve QoL, LVEF, and survival and reduce HF hospitalization in selected patients with AF and HF and/or reduced LVEF.'
        }
      }
    },
    permanentPacing: {
      title: 'Permanent Pacing',
      evidenceLevels: ['B', 'C'],
      content: '**Evidence Level C**: As per ACC/AHA/AMSSM/…/SCMR 2024 guidelines: \n- Consider offering CRT to improve symptoms in patients with HCM and LVEF < 50%, having NYHA class II-IV HF despite guideline-directed medical therapy, and LBBB.\n- Consider offering CRT to improve symptoms in selected adult patients with nonobstructive HCM receiving an ICD and having NYHA class II-IV HF, LBBB, and LVEF < 50%.\n\n**Evidence Level C**: As per ESC 2023 guidelines: \n- Consider performing sequential atrioventricular pacing with optimal atrioventricular interval to reduce the LVOT gradient or to facilitate medical treatment with β-blockers and/or verapamil in selected patients with resting or provoked LVOTO ≥ 50 mmHg, sinus rhythm, and drug-refractory symptoms, having contraindications for alcohol septal ablation or septal myectomy or at high risk of developing heart block following alcohol septal ablation or septal myectomy.\n- Consider placing a dual-chamber implantable cardioverter defibrillator instead of a single-lead device to reduce the LVOT gradient or to facilitate medical treatment with β-blockers and/or verapamil in patients with resting or provoked LVOTO ≥ 50 mmHg, sinus rhythm, and drug-refractory symptoms if there is an indication for an ICD.\n\n**Evidence Level B**: As per ACC/AHA/HRS 2019 guidelines: Perform permanent pacing before discharge in patients with second-degree Mobitz type II AV block, high-grade AV block, or persistent complete AV block after alcohol septal ablation or surgical myectomy.\n\n**Evidence Level C**: Consider selecting a device with defibrillator capabilities in selected patients with HCM requiring permanent pacing for rate support after alcohol septal ablation or surgical myectomy and are at high risk for SCD and meaningful survival of > 1 year is expected.'
    }
  }
}; 